针对针对性的JAK/STAT联合抗PD-1/PD-L1疗法的临床前开发和临床研究
1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China.
International immunopharmacology
|February 22, 2024
概括
瘤通过PD-1/PD-L1相互作用逃避免疫攻击,但耐药性限制了抗PD-1/PD-L1疗法. 针对JAK/STAT途径提供了一种克服这种抗性的策略,并改善癌症治疗结果.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 编程细胞死亡蛋白1 (PD-1) 和它的连接体 (PD-L1) 促进瘤免疫逃避和进展.
- 抗PD-1/PD-L1疗法对一些患者有效,但面临显著的治疗耐药性.
- 克服对PD-1/PD-L1阻断的抵抗对于提高癌症免疫疗法的疗效至关重要.
研究的目的:
- 阐明JAK/STAT信号通路在PD-1/PD-L1表达和抗PD-1/PD-L1治疗反应中的作用.
- 分析JAK/STAT途径中的分子突变与免疫抵抗之间的关联.
- 总结针对JAK/STAT通路和PD-1/PD-L1抑制剂的组合疗法的最新进展.
主要方法:
- 对JAK/STAT路径对PD-1/PD-L1.1的影响现有文献的审查.
- 分析JAK/STAT通路内的分子突变及其与免疫抵抗的相关性.
- 对结合JAK/STAT抑制剂与PD-1/PD-L1阻断的新疗法数据的综合.
主要成果:
- 在JAK/STAT信号通路显著影响PD-1/PD-L1表达.
- 在JAK/STAT途径中的特定分子突变与对PD-1/PD-L1疗法的耐药性有关.
- 新兴的组合疗法在克服治疗耐药性方面表现有前途.
结论:
- JAK/STAT通路是瘤免疫微环境和PD-1/PD-L1表达的关键调节者.
- 针对JAK/STAT通路,特别是在特定突变的背景下,是一个有希望的策略,以提高抗PD-1/PD-L1疗效.
- 涉及JAK/STAT抑制剂和PD-1/PD-L1阻断的组合疗法需要进一步研究,以改善癌症免疫疗法.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524


